Protoporphyrin Imaging in Multispectral Evaluation of Resections
ConditionGlioma
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-99
SponsorMedical University Innsbruck
About this trial
Observational non-interventional investigation to evaluate the potential of multispectral imaging in improving tumor visualization.
Eligibility criteria
Qualifiers
Age Requirement: Patients must be 18 years of age or older.
Diagnosis: Patients with a preoperative diagnosis of a suspected high-grade glioma based demographics and MRI imaging.
Group 1: Suspected high-grade glioma with contrast enhancement on MRI (GBM-like).
Group 2: Suspected high-grade glioma without contrast enhancement on MRI (LGG-like).
Disqualifiers
Patients with a known allergy or contraindication to 5-aminolevulinic acid (5-ALA) or its components.
Use of all other fluorescent markers.
Patients with a history of porphyria or other disorders related to 5-ALA metabolism.
Patients with recurrent gliomas or those who have received prior treatment for their current brain tumor, including surgery, radiotherapy, or chemotherapy.
Trial design
Treatments tested in this trial
- KINEVO 900 S with BLUE 400
Treatment groups
80 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov